Ignite Creation Date:
2024-05-06 @ 8:14 AM
Last Modification Date:
2024-10-26 @ 11:57 AM
Study NCT ID:
NCT02692313
Status:
RECRUITING
Last Update Posted:
2024-03-06
First Post:
2016-02-10
Brief Title:
Dose Response of Epinephrine
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Hypoglycemia Associated Autonomic Dysfunction Dose Response of Epinephrine
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Epineprhine
Brief Summary:
Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 DM Despite this it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans The specific aim of our study will be to determine the dose response effects of the key ANS counterregulatory hormone epinephrine on endothelial function fibrinolytic balance and pro-atherogenic inflammatory mechanisms in healthy humans
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None